Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.98 |
| ▸ | FPR3 | P25089 | 1/20 | 0.98 |
| ▸ | HTR1D | P28221 | 1/20 | 0.98 |
| ▸ | HTR1B | P28222 | 1/20 | 0.98 |
| ▸ | HTR1E | P28566 | 1/20 | 0.98 |
| ▸ | GPR183 | P32249 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | HTR3A | P46098 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498036 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL29462265 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| Hydrochloric Acid SCHEMBL6408286 | 0.99 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL906103 | 0.89 | HTR2C (0.80) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL905843 | 0.86 | HTR2C (0.76) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL905937 | 0.86 | HTR2C (0.76) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL906009 | 0.86 | HTR2C (0.76) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL4928390 | 0.86 | HTR2C (0.76) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL906114 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BHTR1ACHRM4 | |
| SCHEMBL3267229 | 0.84 | HTR2C (0.73) | HTR2CHTR2AHTR2BHTR1ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| EP-3250549-B1 | CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS | UNIV ILLINOIS (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10407381-B2 | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2016123164-A1 | CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | HTR2C 4/4885HTR2A 1/4885HTR2B 5/4885 |
| US-10407381-B2 | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 10/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | HTR2C 4/4885HTR2A 1/4885HTR2B 5/4885 |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | HTR2C 5/4885HTR2A 12/4885HTR2B 15/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2C 1/4885HTR2A 5/4885HTR2B 7/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | HTR2C 4/4885HTR2A 2/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.